Cylene Pharmaceuticals (Sa Diego, CA) a clinical-stage small molecule company focused on broad spectrum anti-proliferative activity against diverse cancer set of cancers, closed a $12M Series D financing. Participants include Sanderling Ventures, HBM BioVentures, Novartis Venture Fund, BioVentures Investors, Lilly Ventures and Morningside Venture Investments.